Biocartis Group NV (EBR: BCART)

Market Cap	27.24M
Revenue (ttm)	60.82M
Net Income (ttm)	-67.87M
Shares Out	93.92M
EPS (ttm)	-0.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112,228
Open	0.290
Previous Close	0.290
Day's Range	0.290 - 0.290
52-Week Range	0.290 - 0.290
Beta	1.33
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 15, 2024

About Biocartis Group NV

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests,...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 526
• Stock Exchange: Euronext Brussels
• Ticker Symbol: BCART

Financial Performance

In 2022, Biocartis Group NV's revenue was 57.98 million, an increase of 5.61% compared to the previous year's 54.90 million. Losses were -65.38 million, -8.52% less than in 2021.